Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RARα isoforms: a study of the PETHEMA group
Fuente:
Zenodo
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Recurso digital |
| Publié: |
Zenodo
2001
|
| Accès en ligne: | |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
| _version_ | 1866901178043858944 |
|---|---|
| author | M. González Barragan, Eva P. Bolufer C. Chillón COLOMER, DOLORS R. Borstein Calasanz, MJ GOMEZ CASARES, MARIA TERESA A. Villegas I. Marugán J. Román G. Martín C. Rayón G. Debén M. Tormo J. Díaz-Mediavilla J. Esteve GONZALEZ SAN MIGUEL, JOSE DAVID C. Rivas K. Pérez-Equiza R. García-Sanz F. J. Capote J. M. Ribera J. Arias A. León M. A. Sanz |
| author_facet | M. González Barragan, Eva P. Bolufer C. Chillón COLOMER, DOLORS R. Borstein Calasanz, MJ GOMEZ CASARES, MARIA TERESA A. Villegas I. Marugán J. Román G. Martín C. Rayón G. Debén M. Tormo J. Díaz-Mediavilla J. Esteve GONZALEZ SAN MIGUEL, JOSE DAVID C. Rivas K. Pérez-Equiza R. García-Sanz F. J. Capote J. M. Ribera J. Arias A. León M. A. Sanz |
| contents | <p>This PETHEMA multicenter study analyzed 167 newly diagnosed PML/RARα-positive acute promyelocytic leukemia (APL) patients treated uniformly under the PETHEMA/LPA96 protocol to assess whether PML/RARα isoforms (bcr-1/L, bcr-2/V, bcr-3/S) are associated with baseline characteristics, response, and outcome. L-form accounted for 50%, V-form 5% and S-form 45%. V- and S-form cases showed a higher frequency of elevated WBC counts at diagnosis; S-form was significantly associated with microgranular M3v morphology and CD34 expression. Complete remission rates were similar across isoforms (overall 90%). Disease-free survival tended to be lower in V-form patients compared with L- and S-form groups, suggesting that V-form and S-form are linked to adverse baseline features, although confirmation in larger uniformly treated series is needed.</p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_18339939 |
| institution | Zenodo |
| language | |
| publishDate | 2001 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RARα isoforms: a study of the PETHEMA group M. González Barragan, Eva P. Bolufer C. Chillón COLOMER, DOLORS R. Borstein Calasanz, MJ GOMEZ CASARES, MARIA TERESA A. Villegas I. Marugán J. Román G. Martín C. Rayón G. Debén M. Tormo J. Díaz-Mediavilla J. Esteve GONZALEZ SAN MIGUEL, JOSE DAVID C. Rivas K. Pérez-Equiza R. García-Sanz F. J. Capote J. M. Ribera J. Arias A. León M. A. Sanz <p>This PETHEMA multicenter study analyzed 167 newly diagnosed PML/RARα-positive acute promyelocytic leukemia (APL) patients treated uniformly under the PETHEMA/LPA96 protocol to assess whether PML/RARα isoforms (bcr-1/L, bcr-2/V, bcr-3/S) are associated with baseline characteristics, response, and outcome. L-form accounted for 50%, V-form 5% and S-form 45%. V- and S-form cases showed a higher frequency of elevated WBC counts at diagnosis; S-form was significantly associated with microgranular M3v morphology and CD34 expression. Complete remission rates were similar across isoforms (overall 90%). Disease-free survival tended to be lower in V-form patients compared with L- and S-form groups, suggesting that V-form and S-form are linked to adverse baseline features, although confirmation in larger uniformly treated series is needed.</p> |
| title | Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RARα isoforms: a study of the PETHEMA group |
| url | https://doi.org/10.5281/zenodo.18339939 |